IMMUNIC, INC. (IMUX) GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - IMMUNIC INC

Explicit Guidance:

• Capitalization & Runway: A secondary PIPE component converting to cash/equity is expected within 30 days of the December INSURE-1/INSURE-2 data readout, yielding an additional $200 million in cash. This capital provides runway extending into the back half of 2028.
• Filing Timeline: The target date for NDA filing is mid-2025 (mid-year).
• Launch Timeline: General guidance for the commercial launch of Vitaflutimus calcium in the US is mid-2026 (mid-year).
• Market Size Projections: The US relapsing MS market is projected to decline from the current $70 billion to $25 billion by the 2030s.

Business-Segment Outlook:

• Product Launch: Planning a US-only commercial launch of Vitaflutimus calcium (an oral tablet) targeting the relapsing MS segment, positioning it as the only therapy with direct neuroprotective properties via NIR1 activation alongside DHODH inhibition.
• Pipeline Expansion: Initiated the third pivotal trial, "Protect MS" (Phase 3), for Progressive MS. The study enrolls 1,400 non-active progressive patients, with first patient enrollment expected in the first half of 2025 and a three-year study duration.
• Commercial Infrastructure: Actively hiring commercial leadership (VP of Marketing, VP of Patient Advocacy) and deploying Medical Science Liaisons to validate go-to-market strategies prior to data readout.
• Target Patient Cohorts: Focus on treatment-naive patients initiating therapy, patients switching therapies (approx. 90,000 annually), and specifically patients on long-term anti-CD20 therapies (3–8 years) seeking safer alternatives due to infection risks or diminishing efficacy.
• Sales Potential: Management notes that capturing 4–5% of the total market share could generate $1 billion in annual sales.

Market and Competitive Outlook:

• Competitive Landscape: Positioned Vitaflutimus calcium against existing oral DMOs (specifically teriflunomide) and potential BTK inhibitors. Differentiation focuses on a "best-in-class" benefit-risk profile with superior safety/tolerability and shorter half-life (30 hours vs. 16–19 days for teriflunomide), allowing for faster clearance (<10 days) and reversibility.
• Market Dynamics: The oral class represents 25–30% of all MS prescriptions and is viewed as ripe for disruption. Management anticipates a significant opportunity to capture patients switching off long-term anti-CD20 therapies (currently ~50% market share) due to unmet safety needs (opportunistic infections, PML risk).
• Efficacy Benchmarks: Phase 2 EMPIRE study showed 42% risk reduction on relapse and 76% reduction in gadolinium-enhancing lesions. Management expects the Phase 3 studies (total 2,221 patients) to maintain efficacy within a comparable range to Phase 2, leveraging the safety profile for adoption.

Macro / Industry Outlook:

• Patient Behavior: Anticipates a shift in patient behavior regarding long-term anti-CD20 usage, with clinicians and patients seeking alternatives after 3–8 years due to cumulative risk concerns.
• Regulatory Path: Awaiting final readout of INSURE-1 and INSURE-2 pivotal trials in December to support NDA filing.

Strategic Initiatives:

• Corporate Pivot: Executed a strategic shift from a development-stage to a pre-commercial entity, evidenced by board turnover and the appointment of new executive leadership (CEO, COO, CMO) with MS commercialization experience.
• Capacity Building: Accelerating efforts to scale commercial infrastructure and launch preparations contingent on successful December data.
• Trial Design: Utilizing "twin" Phase 3 studies (INSURE-1 and INSURE-2) running parallel tracks for a single primary outcome (time to first relapse) with pooled progression analyses using a novel "net clinical benefit" endpoint to capture stability and improvement signals.

Risks and Headwinds to Outlook:

• Clinical Trial Failure: The primary risk remains the failure of the two pivotal Phase 3 studies (INSURE-1/2) to meet statistical significance in December, which would halt the NDA timeline and commercial launch.
• Safety Signals: Potential emergence of tolerability or serious safety issues not captured in the Phase 2 safety database (3,500+ patients) during the larger Phase 3 trials.
• Efficacy Drift: Risk of efficacy signal deterioration when translating from Phase 2 (42% risk reduction) to the larger Phase 3 population, though management notes consistency in baseline demographics.
• Market Competition: Potential entry of BTK inhibitors or other high-efficacy therapies that could compete on efficacy grounds, potentially challenging Vitaflutimus calcium's differentiation on safety.
• Endpoint Limitations: Acknowledgment that the Phase 2 Progress MS study (CALIPER) missed its primary endpoint (whole-brain atrophy), though management argues this metric is a poor predictor of clinical outcomes.

Management Tone on the Future:

• Confidence: High confidence in the safety and tolerability profile ("never seen anything like this") and the mechanistic uniqueness (only therapy targeting neurons directly).
• Hedges: Standard clinical trial disclaimers ("knocking on wood," "hope to see it in that zone") regarding Phase 3 efficacy translation.
• Urgency: Strong emphasis on "preparing for the readout" and accelerating commercial ramp-up immediately following data, indicating a critical window for execution.
• Strategic Focus: Clear pivot to commercialization as the primary mandate, with the board's strategic remit defined specifically around commercializing the lead MS asset.

Miscellaneous:

• Mechanism of Action: Vitaflutimus calcium is a dual-mechanism drug: DHODH inhibition (anti-inflammatory) and NIR1 activation (neuroprotection, gene upregulation for neuronal repair/survival).
• Safety Database: Robust safety data across 3,500 patients, including a placebo-controlled Phase 3 design, showing clean liver and infection profiles with no GI toxicity compared to first-generation DHO-DH inhibitors.
• Half-Life Dynamics: Significant differentiator cited is the short serum half-life (30 hours) enabling rapid clearance compared to teriflunomide (up to 19 days/2 years), addressing concerns for women of childbearing potential.